Molecular medicine in anesthesia
Article Sidebar
Main Article Content
Abstract
The anesthesia’s future suggests to imply molecular biology among its disciplines in order to improve creating personalized therapies. The genes’ analysis allows choosing about drug administration, researching pain medicine, testing techniques and development of new anesthetic agents in order to ensure the efficiency of treatments or procedures
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Powe DG, Keightley A, Chester M, et al. Mucosal thickening in allergic and idiopathic rhinitis mucosa and its probable mechanism. Ann Allergy Asthma Immunol. 2009;103(1):14-9. DOI: https://doi.org/10.1016/S1081-1206(10)60137-8
Mashour GA, Forman SA, Campagna JA. Mechanisms of general anesthesia: from molecules to mind. Best Pract Res Clin Anaesthesiol. 2005;19(3):349-64. DOI: https://doi.org/10.1016/j.bpa.2005.01.004
Baer-Dubowska W, Majchrzak-Celińska A, Cichocki M. Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep. 2011;63(2):293-304. DOI: https://doi.org/10.1016/S1734-1140(11)70498-4
Ruggieri VL, Arberas CL. [Genetic syndromes recognizable in the neonatal period]. Medicina (B Aires). 2009;69(1 Pt 1):15-35.
Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol. 2012;74(4):698-721. DOI: https://doi.org/10.1111/j.1365-2125.2012.04328.x
Wislocki PG, Miwa GT, Lu AY. Reactions catalyzed by the cytochrome P-450 system. En: Jacobi WB, ed. Vol. 1. Enzymatic basis of detoxication. New York: Academic Press; 1980. p. 135-82 DOI: https://doi.org/10.1016/B978-0-12-380001-5.50013-X
Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem. 1987;56:945-93. DOI: https://doi.org/10.1146/annurev.bi.56.070187.004501
Guengerich FP. Reactions and significance of cytochrome P-450 enzymes. J Biol Chem. 1991;266(16):10019-22. DOI: https://doi.org/10.1016/S0021-9258(18)99177-5
Porter TD, Coon MJ. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem. 1991;266(21):13469-72 DOI: https://doi.org/10.1016/S0021-9258(18)92717-1
Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press; 1995. DOI: https://doi.org/10.1007/978-1-4757-2391-5
Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(5):715-29. DOI: https://doi.org/10.1111/j.1365-2036.2006.02980.x
Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336(8709):225-9. DOI: https://doi.org/10.1016/0140-6736(90)91745-V
Hollander AA, van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet. 1995;345(8950):610-4 DOI: https://doi.org/10.1016/S0140-6736(95)90520-0
Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79(3-4):627-30. DOI: https://doi.org/10.1038/sj.bjc.6690098
Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53(22):5433-8.
Uetake H, Ichikawa W, Takechi T, et al. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res. 1999;5(10):2836-9.
Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99-102. DOI: https://doi.org/10.1086/504874
Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603-14. DOI: https://doi.org/10.1016/S0149-2918(01)80132-6
Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171-2. DOI: https://doi.org/10.1345/aph.1E202
Descalzi G, Ikegami D, Ushijima T, et al. Epigenetic mechanisms of chronic pain. Trends Neurosci. 2015;38(4):237-46.Erratum in: Trends Neurosci. 2015;38(9):579. DOI: https://doi.org/10.1016/j.tins.2015.02.001
Fernandez Robles CR, Degnan M, Candiotti KA. Pain and genetics. Curr Opin Anaesthesiol. 2012;25(4):444-9. DOI: https://doi.org/10.1097/ACO.0b013e3283556228
Seo S, Grzenda A, Lomberk G, et al. Epigenetics: a promising paradigm for better understanding and managing pain. J Pain. 2013;14(6):549-57. DOI: https://doi.org/10.1016/j.jpain.2013.01.772
Chen YC, Auer-Grumbach M, Matsukawa S, et al. Transcriptional regulator PRDM12 is essential for human pain perception. Nat Genet. 2015;47(7):803-8. Erratum in: Nat Genet. 2015;47(8):962.
Klepstad P, Rakvåg TT, Kaasa S, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232-9 DOI: https://doi.org/10.1111/j.1399-6576.2004.00517.x
Rakvåg TT, Ross JR, Sato H, et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements incancer patients with pain. Mol Pain. 2008;4:64 DOI: https://doi.org/10.1186/1744-8069-4-64
Flanagan N, Healy E, Ray A, et al. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet. 2000;9(17):2531-7. DOI: https://doi.org/10.1093/hmg/9.17.2531
Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet. 2005;42(7):583-7. DOI: https://doi.org/10.1136/jmg.2004.027698
Fernández Daza PL, Esquinca Cruz MT, Rodríguez MV, Valdespin Pérez R. Porfirias: consideraciones anestésicas. An Med (Mex). 2007;52(3):130-42.
McColl K, Dover S, Fitzsimons E, et al. Porphyrin metabolism and the porphyrias. En: Wheatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine. Oxford: Oxford University Press; 1996. p. 1388-99.
Stoelting RK, Dierdirf SF. Inborn errors of metabolism: anesthesia and co-existing disease. Hines RL, Marschall k. Stoelting’s anesthesia and co-existing disease. 4th ed. Philadelphia, PA: Churchill Livingstone, 2002. p. 455-60.
Baker SD, Taylor B. Anaesthesia is also risky in patients with porphyria. BMJ. 2000;321(7267):1023. DOI: https://doi.org/10.1136/bmj.321.7267.1023
Palmieri C, Vigushin DM, Peters TJ. Managing malignant disease in patients with porphyria. QJM. 2004;97(3):115-26. DOI: https://doi.org/10.1093/qjmed/hch027
Winkler AS, Peters TJ, Marsden JT, et al. Erythropoietin treatment in the neuropsychiatric porphyrias. Clin Chim Acta. 2003;338(1-2):61-6. DOI: https://doi.org/10.1016/j.cccn.2003.07.015
Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006;135(3):281-92. DOI: https://doi.org/10.1111/j.1365-2141.2006.06289.x
Hunter GH. Anesthetic considerations in hepatic porphyrias. CRNA. 1999;10(1):6-14.
Hahn M, Bonkovsky HL. Multiple chemical sensitivity syndrome and porphyria. A note of caution and concern. Arch Intern Med. 1997;157(3):281-5. DOI: https://doi.org/10.1001/archinte.1997.00440240039006
Sheppard L, Dorman T. Anesthesia in a child with homozygous porphobilinogen deaminase deficiency: a severe form of acute intermittent porphyria. Paediatr Anaesth. 2005;15(5):426-8. DOI: https://doi.org/10.1111/j.1460-9592.2005.01451.x